Citation Impact
Citing Papers
Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
2008
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
2009 StandoutNobel
Bump-and-Hole Engineering Identifies Specific Substrates of Glycosyltransferases in Living Cells
2020 StandoutNobel
Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancer
2016 StandoutNobel
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
2008
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
Smarter drugs emerging in pancreatic cancer therapy
2014
A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas
2008
EGFR Antagonists in Cancer Treatment
2008 Standout
Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
2008
Pancreatic cancer
2004 Standout
Testicular Germ-Cell Cancer
1997 Standout
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
Management of borderline and locally advanced pancreatic cancer: Where do we stand?
2014
Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study.
1993
Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.
1995 Standout
Pancreatic cancer
2020 Standout
A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel
2001 Standout
EMT and Dissemination Precede Pancreatic Tumor Formation
2012 Standout
Telomerase inhibition and the future management of head-and-neck cancer
2002
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
1996 Standout
Paclitaxel (Taxol) induces cumulative mild neurotoxicity
1994
Cancer drug resistance: an evolving paradigm
2013 Standout
Advanced pancreatic carcinoma: current treatment and future challenges
2010
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Head and neck cancer
2008 Standout
Paclitaxel (Taxol)
1995 Standout
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
2010 StandoutNature
Pancreatic cancer
2016 Standout
Ligand‐Enabled Triple CH Activation Reactions: One‐Pot Synthesis of Diverse 4‐Aryl‐2‐quinolinones from Propionamides
2014
Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing
1997
G‐Quadruplexes: Targets in Anticancer Drug Design
2008
Advances of capillary electrophoresis in clinical and forensic analysis (1999-2000)
2001
Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.
1993
Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer
1993
Autophagy: Renovation of Cells and Tissues
2011 Standout
Biological Functions of Autophagy Genes: A Disease Perspective
2019 Standout
Pancreatic Adenocarcinoma
2014 Standout
Cancer genes and the pathways they control
2004 Standout
Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors.
1994
Pancreatic cancers require autophagy for tumor growth
2011
Antisense therapy for cancer
2005
Autophagy in Human Health and Disease
2013 Standout
Molecular genetics of prostate cancer
2000
Oncomirs — microRNAs with a role in cancer
2006 Standout
Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer
1996
Human Correlates of Provocative Questions in Pancreatic Pathology
2012
Apoptosis
2002 Standout
Antisense therapy in oncology: new hope for an old idea?
2001
Overview of the clinical efficacy of investigational anticancer drugs
2003
The CDK inhibitors in cancer research and therapy
2011
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
2005 StandoutNature
Role of gemcitabine in cancer therapy
2005
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Pancreatic Cancer
2010 Standout
Tackling the cancer stem cells — what challenges do they pose?
2014
A Phase I trial of h-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma
2001
G-quadruplexes as therapeutic targets
2000
Prostate Stem Cell Antigen Is a Putative Target for Immunotherapy in Pancreatic Cancer
2005
Paclitaxel and its formulations
2002 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Genetics and biology of pancreatic ductal adenocarcinoma
2006
Paclitaxel
1994
Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer
2008
Pancreatic cancer
2011 Standout
miR-30b/30d Regulation of GalNAc Transferases Enhances Invasion and Immunosuppression during Metastasis
2011
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
1999 Standout
Cancer of the Ovary
2004 Standout
3d Transition Metals for C–H Activation
2018 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Supramolecular Coordination: Self-Assembly of Finite Two- and Three-Dimensional Ensembles
2011 Standout
Aptamer-Based Tumor-Targeted Drug Delivery for Photodynamic Therapy
2010
Microfluidics: Fluid physics at the nanoliter scale
2005 Standout
Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
2007
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
2000
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Improving Prospects for Targeting RAS
2015
Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review
2002
Review : Pharmacokinetics and pharmacodynamics of the taxanes
1997
Cyclin-dependent kinases regulate lysosomal degradation of hypoxia-inducible factor 1α to promote cell-cycle progression
2014 StandoutNobel
Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment
2009
Palladium-Catalyzed Transformations of Alkyl C–H Bonds
2016 Standout
Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer
2007
Chemistry and Biology of Taxol
1994
Spermidine in health and disease
2018 StandoutScience
Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma
2001
Nucleic-acid therapeutics: basic principles and recent applications
2002
Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma
2004
Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial
2005
Structural Investigations into the Stereochemistry and Activity of a Phenylalanine-2,3-aminomutase from Taxus chinensis
2014 StandoutNobel
Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer—A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study
2005
Activatable Photosensitizers for Imaging and Therapy
2010 Standout
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer
2006
Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial—SAKK 44/00–CECOG/PAN.1.3.001
2008
Hoxb13is required for normal differentiation and secretory function of the ventral prostate
2003 StandoutNobel
Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies
2007
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
2016
Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic Cancer
2006
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
2009
Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten
2004 StandoutNobel
Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)
2010
Pancreatic Cancer
2008
Evolving concepts in the systemic adjuvant treatment of breast cancer.
1992
4-Aryl-2-quinolones from 3,3-Diarylacrylamides through Intramolecular Copper-Catalyzed C–H Functionalization/C–N Bond Formation
2012
PVT1: A Rising Star among Oncogenic Long Noncoding RNAs
2015
Works of D. Von Hoff being referenced
A phase I trial of taxol given by a 6-hour intravenous infusion.
1991
A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients
2001
A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors
2011
Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial.
1997
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
2005
Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced Cancer
1999
DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications.
1995
Effect of telomere and telomerase interactive agents on human tumor and normal cell lines.
2000
Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer
2004
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16: 1639–1645
2006